We have located links that may give you full text access.
CLINICAL TRIAL
COMPARATIVE STUDY
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Comparing the Differential Diagnostic Values of 18 F-Alfatide II PET/CT between Tuberculosis and Lung Cancer Patients.
Purpose: To compare the differential diagnostic values of 18 F-Alfatide II PET/CT between tuberculosis and lung cancer patients and in patients with sarcoidosis and common inflammation.
Methods: Nine inflammation patients (4 tuberculosis, 3 sarcoidosis, and 2 common inflammation) and 11 lung cancer patients were included in this study. All patients underwent 18 F-FDG and 18 F-Alfatide II PET/CT within 2 weeks, followed by biopsy and surgery. The maximized standard uptake value (SUVmax) and the mean standard uptake value (SUVmean) were evaluated.
Results: The active tuberculosis lesions showed a high accumulation of 18 F-FDG, but varying degrees of accumulation of 18 F-Alfatide II, including negative results. The SUVmax of 18 F-Alfatide II in malignant lesions was significantly higher than that in tuberculosis (4.08 ± 1.51 versus 2.63 ± 1.34, P = 0.0078). Three patients with sarcoidosis showed negative results in 18 F-Alfatide II PET/CT.
Conclusions: The expression of α V β 3 is much lower in tuberculosis as compared to that in lung cancer, and accumulation of 18 F-Alfatide II varied even in lesions of the same patient. The negative results of sarcoidosis patients led to the speculation that α V β 3 was not expressed in those lesions.
Methods: Nine inflammation patients (4 tuberculosis, 3 sarcoidosis, and 2 common inflammation) and 11 lung cancer patients were included in this study. All patients underwent 18 F-FDG and 18 F-Alfatide II PET/CT within 2 weeks, followed by biopsy and surgery. The maximized standard uptake value (SUVmax) and the mean standard uptake value (SUVmean) were evaluated.
Results: The active tuberculosis lesions showed a high accumulation of 18 F-FDG, but varying degrees of accumulation of 18 F-Alfatide II, including negative results. The SUVmax of 18 F-Alfatide II in malignant lesions was significantly higher than that in tuberculosis (4.08 ± 1.51 versus 2.63 ± 1.34, P = 0.0078). Three patients with sarcoidosis showed negative results in 18 F-Alfatide II PET/CT.
Conclusions: The expression of α V β 3 is much lower in tuberculosis as compared to that in lung cancer, and accumulation of 18 F-Alfatide II varied even in lesions of the same patient. The negative results of sarcoidosis patients led to the speculation that α V β 3 was not expressed in those lesions.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app